Project Grant F32AI191456

Award Date 11/1/25
Completion Date Not listed
Dollars Obligated $74K
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Memphis, TN 38105, USA
Similar Awards
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Program (CFDA 93.855) provides $1,172,336.00 to the University of Massachusetts Medical School over a 5-year period starting on August 19, 2024. The goal of the research is to investigate how distinct age-associated B cell subsets can protect the aged from influenza. Specifically, the project will determine the potential of different...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $456,390 to Wake Forest University Health Sciences to conduct research on regulating the immune response to an influenza vaccine in young infants. The key objectives are to understand how varying the duration of antigen delivery impacts the infant B and T cell responses, with the goal of improving the efficacy of influenza vaccines...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under CFDA Program 93.855 Allergy and Infectious Diseases Research, is funding a $556,843 research initiative at the University of Pittsburgh to investigate the development and regulation of the extrafollicular B cell response. The key objectives are to: Examine the role of B cells in enhancing the extrafollicular response and test the self-renewal capacity of the extrafollicular B cell population....
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a 2-year Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) worth $162,000 to The Johns Hopkins University to study how atypical B cells can be used to enhance vaccine responses in immunosuppressed individuals. The research project aims to define populations of immunosuppressed individuals who utilize these atypical CD11c+ B cells, assess their interaction with T cells, and target fatty acid oxidation...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $464,750 to the Icahn School of Medicine at Mount Sinai to investigate the mechanisms of mucosal immune responses induced by mRNA-based and Newcastle Disease Virus (NDV)-based COVID-19 vaccine platforms. The research aims to understand how these vaccine technologies can prime mucosal B cells and promote their recirculation to induce...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $722,958 to the University of Rochester to investigate the role of monocyte-derived galectin-1 in promoting tissue-resident memory T cell responses against influenza virus. The research aims to (1) study monocyte differentiation during immune memory formation after influenza infection, (2) determine how galectin-1...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $149,528 to The Johns Hopkins University to conduct research on the mechanisms underlying sex differences in vaccine-induced immunity. The research aims to investigate how estrogen receptor signaling and mTOR activation in B cells influence metabolic processes and contribute to greater antibody...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $218,068 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to St. Jude Children's Research Hospital Inc. The grant, titled "IMPACT OF OBESITY ON ANTIVIRAL NK CELL FUNCTION AND IMMUNE CROSSTALK WITH RESPIRATORY EPITHELIAL CELLS DURING INFLUENZA VIRUS INFECTION", will fund research to investigate the impact of obesity on natural killer (NK) cell antiviral responses and the...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to gain mechanistic insights into how vaccine adjuvant formulation can overcome immunodominance and stimulate broadly protective antibody responses against influenza. The $1,395,922 award to the Trustees of Indiana University, doing business as Indiana University Indianapolis, will fund research to understand how a Toll-like Receptor 7 (TLR7)...
The University of Texas Health Science Center at San Antonio (UTHSCSA) was awarded a $851,294 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program. The grant, awarded on Jun 20, 2025, supports research to dissect the mechanism of altered immune responses during obesity, with a focus on understanding the role of Tbet+ B cells in impacting vaccine responses and clinical outcomes in obese...

DEFINING MECHANISTIC DRIVERS OF IMPAIRED B CELL RESPONSE TO INFLUENZA A VIRUS VACCINE UNDER CONDITIONS OF OBESITY - PROJECT SUMMARY INFLUENZA A VIRUS (IAV) CAUSES MILLIONS OF INFECTIONS ANNUALLY IN THE UNITED STATES AND WORLDWIDE. ALTHOUGH MANY INFECTIONS RESULT IN MILD RESPIRATORY SYMPTOMS, SOME INDIVIDUALS ARE SUSCEPTIBLE TO SEVERE DISEASE. INDIVIDUALS WITH OBESITY (BMI > 30) INFECTED WITH IAV ARE AT INCREASED RISK FOR RESPIRATORY PATHOLOGY AND DEATH. DATA FROM THE CDC INDICATES APPROXIMATELY 40% OF US ADULTS AND 20% OF CHILDREN ARE OBESE. GIVEN THE HIGH PREVALENCE OF OBESITY AND HIGH CIRCULATION OF IAV, PROTECTING THIS GROUP REPRESENTS A CRITICAL PUBLIC HEALTH ISSUE. VACCINES THAT INDUCE LONG-LIVED PLASMA CELLS AND MEMORY B CELLS CAN DETER SEVERE OUTCOMES ASSOCIATED WITH RESPIRATORY INFECTION. PRIOR RESEARCH FROM OUR LAB AND OTHERS IN IAV VACCINE COHORTS HAS DISPLAYED OBESITY IS CORRELATED WITH IMPAIRED ABILITY TO SUSTAIN LONGITUDINAL B CELL RESPONSES. DESPITE THE OBSERVED IMPAIRMENT OF LONGEVITY OF THESE RESPONSES IN CONDITIONS OF OBESITY, LITTLE IS KNOWN REGARDING THE UNDERLYING MECHANISMS POST-VACCINATION IN THE B CELL LINEAGE THAT DRIVE THE DEFICIENCIES. MOST LONG-LIVED PLASMA CELLS AND MEMORY B CELLS FORMED POST-VACCINATION EMERGE FROM TIGHTLY ORGANIZED GERMINAL CENTER (GC) REACTIONS WHERE ACTIVATED B CELLS BATTLE FOR SURVIVAL AND DIFFERENTIATION SIGNALS FROM CD4+ T FOLLICULAR HELPER CELLS. AIM 1 PROPOSES TO UNCOVER DEFECTS IN THE CELLULAR AND GENETIC MACHINERY OF GC REACTIONS OCCURRING UNDER CONDITIONS OF OBESITY. THIS WILL BE ACHIEVED BY PHENOTYPICALLY PROFILING THE MAGNITUDE AND PERSISTENCE OF VACCINE-INDUCED GC B CELL AND CD4+ T FOLLICULAR HELPER CELL POPULATIONS. PHYSICAL ORGANIZATION OF THE GERMINAL CENTER INTO COMPARTMENTALIZED B AND T CELL REGIONS WILL BE ASSESSED BY MICROSCOPY. TRANSCRIPTOME PROFILES OF GC B CELLS AND CD4+ T FOLLICULAR HELPER CELLS WILL BE ESTABLISHED TO DETERMINE DISRUPTION IN PATHWAYS THAT PROMOTE ESSENTIAL GC PROCESSES AND SUPPORT DIFFERENTIATION INTO PLASMA CELLS AND MEMORY B CELLS. FOLLOWING GC REACTIONS, THE MAINTENANCE OF B CELL-MEDIATED IMMUNITY IS EXECUTED BY TWO DISTINCT CELL TYPES OF THE B CELL LINEAGE, LONG-LIVED PLASMA CELLS AND MEMORY B CELLS. AIM 2 PROPOSES TO DEFINE THE FUNCTIONAL SHORTCOMINGS OF THESE CELLS IN CONDITIONS OF OBESITY AND ESTABLISH ALTERNATIVE VACCINATION STRATEGIES. THE IMPACT OF OBESE CONDITIONS ON THE LONGEVITY OF VACCINE-INDUCED PLASMA CELLS WILL BE QUANTIFIED. THE ABILITY OF MEMORY B CELLS FORMED IN OBESE CONDITIONS TO PROPERLY REACTIVATE WILL BE TESTED EX VIVO, AND THE PROTECTIVE CAPACITY OF THESE CELLS AGAINST HETEROLOGOUS IAV STRAINS WILL BE ASSESSED BY IN VIVO CHALLENGE. THE UTILITY OF BOOSTER SHOTS, HIGH DOSE ANTIGEN, OR MOLECULAR ADJUVANTS WILL BE USED TO ASSESS RESTORATION OF PROPER PLASMA CELL AND MEMORY B CELL LONGEVITY IN OBESE CONDITIONS. IN SUMMARY, THIS PROPOSAL WILL DEFINE THE MECHANISTIC IMPACT OF OBESITY ON PRODUCTIVE B CELL RESPONSES TO IAV VACCINATION AND REVEAL STRATEGIES THAT CAN BOOST PROTECTION IN A VULNERABLE GROUP OF THE HUMAN POPULATION.

Posted 5/1/25